Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (721-730 of 869) with videos related to

Pageof 87
Sort By:
Blood Cancer Discovery|July 16, 2021
ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow MicroenvironmentGiada Bianchi, Peter G Czarnecki, Matthew Ho, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 25, 2017
Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple MyelomaErik H van Beers, Martin H van Vliet, Rowan Kuiper, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 2, 2016
Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myelomaTeru Hideshima, Jun Qi, Ronald M Paranal, et al.
Clinical Lymphoma & Myeloma|June 27, 2006
CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disordersDaniel Ditzel Santos, Evdoxia Hatjiharissi, Olivier Tournilhac, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myelomaPaul G Richardson, Edie Weller, Sundar Jagannath, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2015
The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myelomaGang An, Zengjun Li, Yu-Tzu Tai, et al.
Journal of Medicinal Chemistry|February 24, 2023
Development of a Covalent Inhibitor of c-Jun N-Terminal Protein Kinase (JNK) 2/3 with Selectivity over JNK1Wenchao Lu, Yao Liu, Yang Gao, et al.
Cancer Research|July 3, 2008
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivoConstantine S Mitsiades, Enrique M Ocio, Atanasio Pandiella, et al.
Blood|January 17, 2013
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reactionLian Xu, Zachary R Hunter, Guang Yang, et al.
Cancer|February 15, 2022
Quality of life, psychological distress, and prognostic perceptions in patients with multiple myelomaElizabeth K O'Donnell, Yael N Shapiro, Andrew J Yee, et al.
Pageof 87

Showing results (721-730 of 869) with videos related to

Sort By:
Pageof 87
Blood Cancer Discovery|July 16, 2021
ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow MicroenvironmentGiada Bianchi, Peter G Czarnecki, Matthew Ho, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 25, 2017
Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple MyelomaErik H van Beers, Martin H van Vliet, Rowan Kuiper, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 2, 2016
Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myelomaTeru Hideshima, Jun Qi, Ronald M Paranal, et al.
Clinical Lymphoma & Myeloma|June 27, 2006
CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disordersDaniel Ditzel Santos, Evdoxia Hatjiharissi, Olivier Tournilhac, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myelomaPaul G Richardson, Edie Weller, Sundar Jagannath, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2015
The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myelomaGang An, Zengjun Li, Yu-Tzu Tai, et al.
Journal of Medicinal Chemistry|February 24, 2023
Development of a Covalent Inhibitor of c-Jun N-Terminal Protein Kinase (JNK) 2/3 with Selectivity over JNK1Wenchao Lu, Yao Liu, Yang Gao, et al.
Cancer Research|July 3, 2008
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivoConstantine S Mitsiades, Enrique M Ocio, Atanasio Pandiella, et al.
Blood|January 17, 2013
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reactionLian Xu, Zachary R Hunter, Guang Yang, et al.
Cancer|February 15, 2022
Quality of life, psychological distress, and prognostic perceptions in patients with multiple myelomaElizabeth K O'Donnell, Yael N Shapiro, Andrew J Yee, et al.
Pageof 87